从1994年 FGFR3靶点被证实与ACH相关，到2021年Vosoritide获批上市，ACH患者等待了近30年，才迎来首款针对性治疗药物。而随着Infigratinib叩响上市的大门，以及身后一众迭代疗法的逼近，ACH精准治疗的新大门正加速开启。这也是罕见病从被行业忽略到逐渐被重视的真实缩影。
90.1%64/71 picks
，推荐阅读爱思助手下载最新版本获取更多信息
generate images that are not entirely original and could be influenced by
At least 57 of those that will miss the deadline are aiming to launch their service for all households by the end of 2026. More than a dozen could not give an approximate start date.